Currently, no biomarkers can accurately predict survival outcomes in patients with SCLC undergoing treatment. Tumor growth rate (TGR; percent size change per month [%/m]) is suggested as an imaging predictor… Click to show full abstract
Currently, no biomarkers can accurately predict survival outcomes in patients with SCLC undergoing treatment. Tumor growth rate (TGR; percent size change per month [%/m]) is suggested as an imaging predictor of response to anti‐cancer treatment. We aimed to evaluate the predictive role of the maximum TGR (TGRmax) for outcomes of small‐cell lung cancer (SCLC) patients undergoing first‐line chemotherapy plus immune‐checkpoint inhibitor (ICI) treatment.
               
Click one of the above tabs to view related content.